½ÃÀ庸°í¼­
»óǰÄÚµå
1720837

¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå º¸°í¼­(2025³â)

Nephrotic Syndrome Global Market Report 2025

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Business Research Company | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ÅÁõÈıº ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ½ÅÁõÈıº¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¸¸¼º ½ÅÀå Áúȯ(CKD) À¯º´·ü Áõ°¡, ´ë»ç Àå¾Ö ¹ß»ý·ü Áõ°¡, Àα¸ °í·ÉÈ­, ÀÚ°¡ ¸é¿ª ÁúȯÀÇ ¹ß»ý Áõ°¡¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä Æ®·»µå¿¡´Â ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µÀÇ È®´ë, ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀü, Ä¡·á ¹æ½ÄÀÇ Çõ½Å, »ý¸í°øÇÐÀÇ ¹ßÀü, µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕÀÌ Æ÷ÇԵ˴ϴÙ.

½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÅÁõÈıº ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÅÀå ÁúȯÀº Ç÷¾×¿¡¼­ ³ëÆó¹°°ú °úµµÇÑ Ã¼¾×À» °É·¯³»´Â ½ÅÀåÀÇ ´É·ÂÀ» ¼Õ»ó½ÃŰ´Â ´Ù¾çÇÑ »óŸ¦ Æ÷°ýÇÕ´Ï´Ù. ½ÅÀå ÁúȯÀÇ ¹ßº´·üÀ» ³ôÀÌ´Â ¿äÀÎÀ¸·Î´Â ´ç´¢º´, °íÇ÷¾Ð, ºñ¸¸, Àα¸ °í·ÉÈ­, ³ôÀº ³ªÆ®·ý ¼·Ãë ¹× ºÎÀûÀýÇÑ ¼öºÐ ¼·Ãë¿Í °°Àº »ýȰ ½À°ü º¯È­ µîÀÌ ÀÖ½À´Ï´Ù. ½ÅÁõÈıºÀº »ç±¸Ã¼¸¦ ¼Õ»ó½ÃŰ°í ¿©°ú¿Í ´Ü¹éÁú º¸À¯¸¦ ¹æÇØÇÏ¿© ½ÅÀå ÁúȯÀ» ¾ÇÈ­½Ãŵ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 6¿ù È£ÁÖ Á¤ºÎ ±â°üÀΠȣÁÖ º¸°Ç º¹Áö ¿¬±¸¼Ò´Â È£ÁÖÀÇ ¸¸¼º ½ÅÀå Áúȯ(CKD) »ç¸Á·üÀÌ 2021³â 4.2%¿¡¼­ 2022³â 6.2%·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. °á°úÀûÀ¸·Î ½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÅÁõÈıº ½ÃÀåÀÇ È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÅÁõÈıº ½ÃÀåÀ» ¼±µµÇÏ´Â ±â¾÷µéÀº ½ÅÁõÈıº ȯÀÚÀÇ Ã¼¾× °ü¸®¸¦ °³¼±ÇÏ°í ºÎÁ¾À» ÁÙÀ̱â À§ÇØ ·çÇÁ ÀÌ´¢Á¦ ÁÖ»ç¿Í °°Àº Çõ½ÅÀûÀÎ Á¦Çü °³¹ß¿¡ ¿ì¼±¼øÀ§¸¦ µÎ°í ÀÖ½À´Ï´Ù. ·çÇÁ ÀÌ´¢Á¦ ÁÖ»ç´Â Çî·¹ ·çÇÁ¿¡¼­ ³ªÆ®·ý°ú ¿°È­¹° ÀçÈí¼ö¸¦ Â÷´ÜÇÏ¿© ºü¸¥ ¼Òº¯ »ý¼ºÀ» ÃËÁøÇÏ´Â ÁÖ»çÁ¦ÀÔ´Ï´Ù. ü¾× °úºÎÇϸ¦ ÁÙ¿© ±Þ¼º ÆóºÎÁ¾, ½ÉºÎÀü, ÁßÁõ °íÇ÷¾Ð°ú °°Àº ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 3¿ù ¹Ì±¹ Á¦¾à ȸ»çÀÎ Avenacy´Â ¹Ì±¹ ½ÄǰÀǾ౹À¸·ÎºÎÅÍ ½ÉºÎÀü, °£°æº¯ ¹× ½ÅÀå Áúȯ°ú °ü·ÃµÈ ºÎÁ¾ Ä¡·áÁ¦·Î ½ÂÀÎÀ» ¹ÞÀº ¶ó½Ä½ºÀÇ Á¦³×¸¯ÀΠǪ·Î¼¼¹Ìµå ÁÖ»çÁ¦¸¦ ¹Ì±¹¿¡¼­ Ãâ½ÃÇß½À´Ï´Ù. 100mg/10mL ¿ë·®À¸·Î 25°³ ´ÜÀ§ ÆÑÀ¸·Î Æ÷ÀåµÈ À̹ø Ãâ½Ã´Â 2024³â±îÁö 20°³ ÀÌ»óÀÇ Á¦Ç°À» Ãâ½ÃÇÒ °èȹÀÎ AvenacyÀÇ ±¤¹üÀ§ÇÑ ÁÖ»çÁ¦ Æ÷Æ®Æú¸®¿À È®Àå Àü·«ÀÇ ÀÏȯÀÔ´Ï´Ù. ÀÌ ¾à¹°Àº ¿ïÇ÷¼º ½ÉºÎÀü, °£°æº¯, ½ÅÁõÈıºÀ» Æ÷ÇÔÇÑ ½ÅÀå Áúȯ°ú °ü·ÃµÈ ºÎÁ¾ÀÌ ÀÖ´Â ¼ºÀÎ ¹× ¼Ò¾Æ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

  • ¼¼°èÀÇ ½ÅÁõÈıº PESTEL ºÐ¼®(Á¤Ä¡, »çȸ, ±â¼ú, ȯ°æ, ¹ýÀû ¿äÀÎ, ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ)
  • ÃÖÁ¾ ÀÌ¿ë »ê¾÷ÀÇ ºÐ¼®
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : ¼ºÀå·ü ºÐ¼®
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå ½ÇÀû : ±Ô¸ð¿Í ¼ºÀå(2019-2024³â)
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå ¿¹Ãø : ±Ô¸ð¿Í ¼ºÀå(2024-2029³â, 2034³â)
  • ¼¼°èÀÇ ½ÅÁõÈıº ÃÑ ½ÃÀå ±Ô¸ð(TAM)

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : À¯Çüº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ¾à¹°
  • µð¹ÙÀ̽º
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : Áø´Ü °Ë»çº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ¼Òº¯ °Ë»ç
  • »ç±¸Ã¼ ¿©°úÀ²(GFR)
  • Ç÷¾× °Ë»ç
  • ½ÅÀå »ý°Ë
  • ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ(CT) ½ºÄµ
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : ¿ëµµº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • Ŭ¸®´Ð
  • º´¿ø
  • Àü¹®¼¾ÅÍ
  • ±âŸ ¿ëµµ
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : ¾à¹° À¯Çüº° ¼¼ºÐÈ­, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ½ºÅ×·ÎÀ̵å
  • ¸é¿ª ¾ïÁ¦Á¦
  • ÀÌ´¢Á¦
  • ACE ¾ïÁ¦Á¦ ¶Ç´Â ARB
  • ±âŸ ¾à¹°
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : µð¹ÙÀ̽º À¯Çüº° ¼¼ºÐÈ­, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • Åõ¼® ÀåÄ¡
  • º¹¸· Åõ¼® Ä«Å×ÅÍ
  • Ç÷¾× Åõ¼® Ä«Å×ÅÍ
  • ½ÅÀå ´ëü Ä¡·á ÀåÄ¡

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : Áö¿ªº°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
  • ¼¼°èÀÇ ½ÅÁõÈıº ½ÃÀå : ±¹°¡º°, ºÐ¼®°ú ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ½ÅÁõÈıº ½ÃÀå : °æÀï ±¸µµ
  • ½ÅÁõÈıº ½ÃÀå : ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Pfizer Inc. °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • F. Hoffmann-La Roche AG °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • AbbVie Inc. °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • Bristol-Myers Squibb Company °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®
    • Abbott Laboratories °³¿ä, Á¦Ç° ¹× ¼­ºñ½º, Àü·« ¹× À繫 ºÐ¼®

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

  • Novartis AG
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • Otsuka Pharmaceutical Co. Ltd.
  • Astellas Pharma Inc.
  • Vertex Pharmaceuticals
  • Chugai Pharmaceutical Co. Ltd.
  • Mallinckrodt Company
  • Evotec SE
  • Travere Therapeutics Inc.
  • Aurinia Pharmaceuticals Inc.
  • Orbis Biosciences Inc.
  • Alpine Immune Sciences

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

  • ½ÅÁõÈıº ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
  • ½ÅÁõÈıº ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
  • ½ÅÁõÈıº ½ÃÀå(2029³â) : ¼ºÀå Àü·«
    • ½ÃÀå µ¿Çâ¿¡ ±âÃÊÇÑ Àü·«
    • °æÀï Àü·«

Á¦36Àå ºÎ·Ï

HBR 25.05.19

Nephrotic syndrome is a kidney disorder characterized by excessive protein loss in the urine (proteinuria), low blood protein levels (hypoalbuminemia), high cholesterol levels (hyperlipidemia), and swelling (edema), particularly in the legs, feet, and around the eyes. It results from damage to the glomeruli, the kidney's filtering units, allowing protein to leak into the urine.

The primary types of nephrotic syndrome treatment include drugs and devices. Drugs are substances used to diagnose, treat, or prevent diseases by modifying bodily functions. Diagnosis of nephrotic syndrome involves various tests, such as urinalysis, glomerular filtration rate (GFR) measurement, blood tests, kidney biopsy, and computerized tomography (CT) scans. The key applications span clinics, hospitals, specialty centers, and other healthcare facilities.

The nephrotic syndrome market research report is one of a series of new reports from The Business Research Company that provides nephrotic syndrome market statistics, including the nephrotic syndrome industry global market size, regional shares, competitors with the nephrotic syndrome market share, detailed nephrotic syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the nephrotic syndrome industry. This nephrotic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nephrotic syndrome market size has grown rapidly in recent years. It will grow from $0.87 billion in 2024 to $00.96 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period can be attributed to the rising incidence of nephrotic syndrome, an increase in genetic disorders, growing obesity rates, the expanded use of immunosuppressive medications, and the increasing impact of genetic factors.

The nephrotic syndrome market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth during the forecast period can be attributed to increasing awareness of nephrotic syndrome, a rising prevalence of chronic kidney disease (CKD), a growing incidence of metabolic disorders, an aging population, and a higher occurrence of autoimmune diseases. Key trends in the forecast period include the expansion of telemedicine and remote monitoring, advancements in drug delivery systems, innovations in treatment modalities, progress in biotechnology, and the integration of digital health technologies.

The rising prevalence of kidney diseases is expected to drive the growth of the nephrotic syndrome market. Kidney diseases encompass various conditions that impair the kidneys' ability to filter waste and excess fluids from the blood. Factors contributing to the increasing incidence of kidney diseases include diabetes, hypertension, obesity, aging populations, and lifestyle changes such as high sodium intake and inadequate hydration. Nephrotic syndrome exacerbates kidney diseases by damaging the glomeruli, impairing filtration and protein retention. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that the percentage of chronic kidney disease (CKD) mortality in the country increased from 4.2% in 2021 to 6.2% in 2022. As a result, the growing prevalence of kidney diseases is fueling the expansion of the nephrotic syndrome market.

Leading companies in the nephrotic syndrome market are prioritizing the development of innovative formulations, such as loop diuretic injections, to enhance fluid management and reduce edema in nephrotic syndrome patients. Loop diuretic injection is an injectable medication that blocks sodium and chloride reabsorption in the loop of Henle, promoting rapid urine production. It is commonly used to treat conditions such as acute pulmonary edema, heart failure, and severe hypertension by reducing fluid overload. For instance, in March 2024, Avenacy Inc., a US-based pharmaceutical company, launched furosemide for injection in the U.S., a generic equivalent to Lasix, which received approval from the Food and Drug Administration for treating edema related to heart failure, liver cirrhosis, and kidney diseases. Packaged in 25-unit packs of 100 mg/10 mL doses, this launch is part of Avenacy's broader strategy to expand its injectable medication portfolio, with plans to introduce more than 20 products in 2024. This drug is indicated for adult and pediatric patients with edema associated with congestive heart failure, liver cirrhosis, and renal disease, including nephrotic syndrome.

In August 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired Chinook Therapeutics for $3.5 billion. This acquisition aims to strengthen Novartis' renal portfolio by incorporating Chinook Therapeutics' late-stage assets, atrasentan and zigakibart, which are being developed for the treatment of Immunoglobulin A Nephropathy (IgAN). The acquisition aligns with Novartis' strategic focus on innovative medicines. Chinook Therapeutics, a US-based biopharmaceutical company, specializes in developing treatments for nephrotic syndrome.

Major players in the nephrotic syndrome market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Eli Lilly and Company, Asahi Kasei Corporation, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Vertex Pharmaceuticals, Chugai Pharmaceutical Co. Ltd., Mallinckrodt Company, Evotec SE, Travere Therapeutics Inc., Aurinia Pharmaceuticals Inc., Orbis Biosciences Inc., Alpine Immune Sciences, Kezar Life Sciences, Zenyaku Kogyo Co. Ltd.

North America was the largest region in the nephrotic syndrome market in 2024. The regions covered in nephrotic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nephrotic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nephrotic syndrome market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, dialysis services, and kidney transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nephrotic syndrome market also includes sales of diuretics, anticoagulants, immunosuppressants, ACE inhibitors and Arbs and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nephrotic Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nephrotic syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nephrotic syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nephrotic syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Drugs; Devices
  • 2) By Diagnosis Tests: Urinalysis; Glomerular Filtration Rate (GFR); Blood Test; Kidney Biopsy; Computerized Tomography (CT) Scan
  • 3) By Application: Clinics; Hospitals; Speciality Centres; Other Applications
  • Subsegments:
  • 1) By Drugs: Steroids; Immunosuppressants; Diuretics; ACE Inhibitors Or ARBs; Other Drugs
  • 2) By Devices: Dialysis Machines; Peritoneal Dialysis Catheters; Hemodialysis Catheters; Kidney Replacement Therapy Devices
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bristol-Myers Squibb Company; Abbott Laboratories
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nephrotic Syndrome Market Characteristics

3. Nephrotic Syndrome Market Trends And Strategies

4. Nephrotic Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Nephrotic Syndrome Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Nephrotic Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Nephrotic Syndrome Market Growth Rate Analysis
  • 5.4. Global Nephrotic Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Nephrotic Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Nephrotic Syndrome Total Addressable Market (TAM)

6. Nephrotic Syndrome Market Segmentation

  • 6.1. Global Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drugs
  • Devices
  • 6.2. Global Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Urinalysis
  • Glomerular Filtration Rate (GFR)
  • Blood Test
  • Kidney Biopsy
  • Computerized Tomography (CT) Scan
  • 6.3. Global Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinics
  • Hospitals
  • Speciality Centres
  • Other Applications
  • 6.4. Global Nephrotic Syndrome Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Steroids
  • Immunosuppressants
  • Diuretics
  • ACE Inhibitors Or ARBs
  • Other Drugs
  • 6.5. Global Nephrotic Syndrome Market, Sub-Segmentation Of Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dialysis Machines
  • Peritoneal Dialysis Catheters
  • Hemodialysis Catheters
  • Kidney Replacement Therapy Devices

7. Nephrotic Syndrome Market Regional And Country Analysis

  • 7.1. Global Nephrotic Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Nephrotic Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nephrotic Syndrome Market

  • 8.1. Asia-Pacific Nephrotic Syndrome Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nephrotic Syndrome Market

  • 9.1. China Nephrotic Syndrome Market Overview
  • 9.2. China Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nephrotic Syndrome Market

  • 10.1. India Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nephrotic Syndrome Market

  • 11.1. Japan Nephrotic Syndrome Market Overview
  • 11.2. Japan Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nephrotic Syndrome Market

  • 12.1. Australia Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nephrotic Syndrome Market

  • 13.1. Indonesia Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nephrotic Syndrome Market

  • 14.1. South Korea Nephrotic Syndrome Market Overview
  • 14.2. South Korea Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nephrotic Syndrome Market

  • 15.1. Western Europe Nephrotic Syndrome Market Overview
  • 15.2. Western Europe Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nephrotic Syndrome Market

  • 16.1. UK Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nephrotic Syndrome Market

  • 17.1. Germany Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nephrotic Syndrome Market

  • 18.1. France Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nephrotic Syndrome Market

  • 19.1. Italy Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nephrotic Syndrome Market

  • 20.1. Spain Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nephrotic Syndrome Market

  • 21.1. Eastern Europe Nephrotic Syndrome Market Overview
  • 21.2. Eastern Europe Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nephrotic Syndrome Market

  • 22.1. Russia Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nephrotic Syndrome Market

  • 23.1. North America Nephrotic Syndrome Market Overview
  • 23.2. North America Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nephrotic Syndrome Market

  • 24.1. USA Nephrotic Syndrome Market Overview
  • 24.2. USA Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nephrotic Syndrome Market

  • 25.1. Canada Nephrotic Syndrome Market Overview
  • 25.2. Canada Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nephrotic Syndrome Market

  • 26.1. South America Nephrotic Syndrome Market Overview
  • 26.2. South America Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nephrotic Syndrome Market

  • 27.1. Brazil Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nephrotic Syndrome Market

  • 28.1. Middle East Nephrotic Syndrome Market Overview
  • 28.2. Middle East Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nephrotic Syndrome Market

  • 29.1. Africa Nephrotic Syndrome Market Overview
  • 29.2. Africa Nephrotic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Nephrotic Syndrome Market, Segmentation By Diagnosis Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Nephrotic Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nephrotic Syndrome Market Competitive Landscape And Company Profiles

  • 30.1. Nephrotic Syndrome Market Competitive Landscape
  • 30.2. Nephrotic Syndrome Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Nephrotic Syndrome Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. GlaxoSmithKline plc
  • 31.3. Amgen Inc.
  • 31.4. Eli Lilly and Company
  • 31.5. Asahi Kasei Corporation
  • 31.6. Otsuka Pharmaceutical Co. Ltd.
  • 31.7. Astellas Pharma Inc.
  • 31.8. Vertex Pharmaceuticals
  • 31.9. Chugai Pharmaceutical Co. Ltd.
  • 31.10. Mallinckrodt Company
  • 31.11. Evotec SE
  • 31.12. Travere Therapeutics Inc.
  • 31.13. Aurinia Pharmaceuticals Inc.
  • 31.14. Orbis Biosciences Inc.
  • 31.15. Alpine Immune Sciences

32. Global Nephrotic Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nephrotic Syndrome Market

34. Recent Developments In The Nephrotic Syndrome Market

35. Nephrotic Syndrome Market High Potential Countries, Segments and Strategies

  • 35.1 Nephrotic Syndrome Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Nephrotic Syndrome Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Nephrotic Syndrome Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦